CA2861074C - Mtb-c vaccine against asthma - Google Patents

Mtb-c vaccine against asthma Download PDF

Info

Publication number
CA2861074C
CA2861074C CA2861074A CA2861074A CA2861074C CA 2861074 C CA2861074 C CA 2861074C CA 2861074 A CA2861074 A CA 2861074A CA 2861074 A CA2861074 A CA 2861074A CA 2861074 C CA2861074 C CA 2861074C
Authority
CA
Canada
Prior art keywords
agent
use according
liposome
mtb
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2861074A
Other languages
English (en)
French (fr)
Other versions
CA2861074A1 (en
Inventor
Pere-Joan Cardona Iglesias
Isabel Amat Riera
Blanca REYES MORENO
Maria Merce Amat Fabregat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archivel Farma SL
Original Assignee
Archivel Farma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma SL filed Critical Archivel Farma SL
Publication of CA2861074A1 publication Critical patent/CA2861074A1/en
Application granted granted Critical
Publication of CA2861074C publication Critical patent/CA2861074C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2861074A 2012-01-12 2012-01-12 Mtb-c vaccine against asthma Active CA2861074C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (2)

Publication Number Publication Date
CA2861074A1 CA2861074A1 (en) 2013-07-18
CA2861074C true CA2861074C (en) 2018-11-06

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2861074A Active CA2861074C (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Country Status (15)

Country Link
US (1) US9682042B2 (enExample)
EP (1) EP2802345B1 (enExample)
CN (1) CN104411326B (enExample)
AU (1) AU2012365465B2 (enExample)
BR (1) BR112014017217B1 (enExample)
CA (1) CA2861074C (enExample)
DK (1) DK2802345T3 (enExample)
ES (1) ES2670493T3 (enExample)
IN (1) IN2014MN01594A (enExample)
NO (1) NO2802345T3 (enExample)
PL (1) PL2802345T3 (enExample)
PT (1) PT2802345T (enExample)
RU (1) RU2602771C2 (enExample)
WO (1) WO2013104943A1 (enExample)
ZA (1) ZA201405107B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法，及其制备的可变性脂质体
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) * 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Also Published As

Publication number Publication date
AU2012365465A1 (en) 2014-08-21
CA2861074A1 (en) 2013-07-18
EP2802345B1 (en) 2018-03-07
DK2802345T3 (en) 2018-04-30
ES2670493T3 (es) 2018-05-30
AU2012365465B2 (en) 2017-05-18
PL2802345T3 (pl) 2018-08-31
NO2802345T3 (enExample) 2018-08-04
CN104411326B (zh) 2018-02-02
US20150132364A1 (en) 2015-05-14
PT2802345T (pt) 2018-04-24
EP2802345A1 (en) 2014-11-19
WO2013104943A1 (en) 2013-07-18
ZA201405107B (en) 2020-11-25
RU2014133042A (ru) 2016-02-27
RU2602771C2 (ru) 2016-11-20
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
US9682042B2 (en) 2017-06-20
CN104411326A (zh) 2015-03-11
IN2014MN01594A (enExample) 2015-05-08
BR112014017217A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CA2823747C (en) Liposome formulation suitable for treating or preventing tuberculosis
RU2526910C2 (ru) Профилактическая вакцина от туберкулеза
Ozberk et al. A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils
AU2012365465B2 (en) MTB-C vaccine against asthma
US8795719B2 (en) Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
US20260137766A1 (en) Liposome formulations for treatment of active tuberculosis
KR20180132178A (ko) 비피막형 헤모필루스 인플루엔자 백신 및 그의 용도
EP2471511A1 (en) Liposome formulation suitable for treating or preventing tuberculosis
EA053229B1 (ru) Применение липосомных композиций для лечения активной формы туберкулеза
HK1171659A (en) Liposome formulation suitable for treating or preventing tuberculosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160713

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250714

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106